11:26 AM EST, 02/18/2025 (MT Newswires) -- (Updates with recent stock movement in the headline and first paragraph.)

GeneDx ( WGS ) shares were advancing almost 35% in recent Tuesday trading after the company reported Q4 results that were better than expected and issued 2025 revenue guidance above analysts' estimates.

The company reported adjusted net income of $16.8 million for the quarter ended Dec. 31, compared with an adjusted net loss of $17.8 million a year earlier. Two analysts surveyed by FactSet expected $1.6 million.

Revenue was $95.6 million, up from $58.1 million a year earlier. Analysts surveyed by FactSet expected $82.2 million.

For the full year, GeneDx ( WGS ) expects revenue between $350 million and $360 million, with growth in exome/genome volume and revenue of at least 30%. Analysts surveyed by FactSet expect $338.8 million.

Price: 102.72, Change: +26.37, Percent Change: +34.54